Significance of Findings in RESPONSE Trial in Polycythemia Vera

Jean-Jaques Kiladjian, MD, PhD, professor of clinical pharmacology at Paris Diderot University, discusses how the results from the RESPONSE trial impact patients with polycythemia vera (PV).

For patients with PV who are resistant to hydroxyurea, their outcomes have generally been very poor with a reduced life expectancy and high risk of vascular complications, according to Kiladjian. Ruxolitinib (Jakafi) treatment has given these patients an opportunity for treatment with good efficacy and safety.